Prespecified exploratory secondary analysis of a phase 3 trial in 903 adults with nondiabetic CKD due to glomerular disease: finerenone vs placebo slowed total eGFR decline (−3.50 vs −4.23 mL/min/1.73 m² per year; difference 0.73, 95% CI 0.22–1.24) over 32 months.
Secondary analysisn = 903
Neuen et al. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial